Vaishali Pharma Limited (VAISHALI) Fair Value & Analysis
Healthcare · IN · Market cap ₹952M
Fair value as of: Jul 3, 2026
From 17 valuation models · updated today
Share price +2.0% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹4.88 – ₹13.15 · fair‑value band ₹4.07 – ₹6.07 · the ₹7.31 price screens above the ₹4.29 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Vaishali Pharma Limited (VAISHALI) currently trades at ₹7.31, while our model-based Fair Value estimate is ₹4.29 — implying the stock looks roughly 41.3% overvalued today. We read business quality at 34/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Vaishali Pharma Limited generated revenue of ₹1.1B at a net margin of 3.8%. Revenue declined 16.5% year over year. It earns a return on equity of 6.2%. Net debt stands at ₹175M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti"malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides formulations, including antibiotics, antibacterial, anti-platelet, laxative, anti-ulcer, enzymes, anti-asthmatic, anti-malarial, anti-cold, anti-allergic, anti-viral, anti-psychotic, anti-fungal, vitamins, topical steroids, corticosteroids, anti-inflammatory, analgesic, anti-pyretic, anti-diabetic, cardiac, and other products. In addition, it offers disposable surgical and casting tape products; herbal products; veterinary products; …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Vaishali Pharma Limited reported revenue of ₹1.1B in FY2026 versus ₹758M in FY2022, a compound +9.4%/yr. Reported net income was ₹41.6M in FY2026, compounding +0.9%/yr from FY2022.
Is VAISHALI fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,863 | ₹1,039 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Vaishali Pharma Limited (VAISHALI) undervalued?
What is the fair value of VAISHALI?
What is the quality score of VAISHALI?
What is the revenue of Vaishali Pharma Limited (VAISHALI)?
What is the net profit margin of VAISHALI?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.